Evaluation of the Adherence and the Patient Acceptability of Zomacton® Treatment With the Zomajet® Vision X Device

N/ATerminatedNCT02018172

Ferring Pharmaceuticals3 enrolled

Overview

The study is performed to collect long-term data on the treatment adherence and patient's acceptability when Zomacton®10 mg is administered with the Zomajet® Vision X device in patients with a growth hormone deficiency or Turner's syndrome.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Growth Hormone Deficiency Turner's Syndrome

Interventions

somatropinDRUG

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Patient with growth hormone deficiency, 1. Diagnosis of growth hormone deficiency proven by appropriate exploration 2. Size ≤ -2 Standard Deviation (SD) according to the French references 3. Growth velocity in the previous year inferior to the normal for age (-1SD) or \< 4cm/year * Growth deficiency due to Turner's syndrome 1. Turner's syndrome confirmed by a karyotype 2. Patient's size ≤ -2 SD according to the French references 3. Bone age \< 12 years * Patient who require a minimum of 18 months of treatment. Exclusion Criteria: * There are no exclusion criteria except the contraindication for Zomacton® 10 mg

Locations (1)

Hôpital des Enfants, CHU de Toulouse

Toulouse, France

Outcomes

Primary Outcomes

Rate of overall treatment adherence

Ratio between actual duration of administration and total duration recommended by physician

Time frame: Up to 18 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.